This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gentiva® Health Services Provides 2013 Outlook

ATLANTA, March 20, 2013 /PRNewswire/ -- Gentiva Health Services, Inc. (NASDAQ: GTIV) announced today its 2013 financial outlook for net revenues and adjusted income from continuing operations attributable to Gentiva shareholders.  This outlook reflects the recently issued instructions from the Centers for Medicare & Medicaid Services (CMS) regarding the treatment of sequestration.

For the full-year 2013, the Company expects:
  • Net revenues to be in the range of $1.69 billion to $1.73 billion, including a $21.0 million year-over-year negative impact from branches closed or sold in the prior year.
  • Adjusted income from continuing operations attributable to Gentiva shareholders to be in the range of $0.90 to $1.10 on a diluted per share basis, based on an estimated 31.0 million shares outstanding.

This guidance includes the negative impact of sequestration and Medicare related rate changes, which is an approximate $30.0 million reduction in net revenues and adjusted earnings before interest, taxes, depreciation and amortization attributable to continuing operations (Adjusted EBITDA) and a $0.60 reduction in adjusted income from continuing operations on a diluted per share basis. This guidance assumes that sequestration will affect the reimbursement related to Medicare patients whose service dates end on or after April 1, 2013.

This guidance does not include the potential impact of acquisitions, credit agreement amendments or future reimbursement rate changes. Adjusted income from continuing operations attributable to Gentiva shareholders and Adjusted EBITDA exclude charges related to restructuring, legal settlements, acquisition and integration activities and other special items.

Free cash flow is expected to be in the range of $40.0 to $50.0 million for the full-year 2013.  No further principal payments are due this year under the Company's credit agreement as the Company prepaid the $25.0 million due in February 2013.  Based on this debt prepayment and typical cash flow seasonality, the Company expects its cash flow to be lower in the first quarter of 2013, but to increase as the year progresses. Free cash flow is calculated as net cash provided by operating activities less capital expenditures.

"Against another difficult reimbursement year, our focus in 2013 is squarely on continuing to drive strong mid-single digit home health growth and on returning our hospice division to consistent growth to offset the impact of these cuts," said Gentiva CEO Tony Strange. "We remain committed to delivering the message to policy makers and legislators that home health and hospice are cost effective, clinically appropriate and patient preferred, and consequently, we expect our industry to receive the reimbursement clarity it desperately needs as we get into the second half of the year."

Non-GAAP Financial Measures

The information provided in this press release includes certain non-GAAP financial measures as defined under Securities and Exchange Commission rules. A reconciliation of adjusted income from continuing operations attributable to Gentiva shareholders to net income, the most directly comparable GAAP measure, is not accessible on a forward-looking basis without unreasonable effort due to the inherent difficulties in predicting the costs of restructuring, legal settlements and merger and acquisition activities, the results of discontinued operations and the impact of any future acquisitions or divestitures, which can fluctuate significantly and may have a significant impact on net income.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs